Litigation Details for ASTRAZENECA AB v. APOTEX CORP. (D.N.J. 2015)

ASTRAZENECA AB v. APOTEX CORP. (D.N.J. 2015)

Docket		Date Filed	2015-05-15
Court	District Court, D. New Jersey	Date Terminated	2017-06-05
Cause	35:271 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	None	Referred To	Douglas Arpert
Parties	APOTEX INC.
Patents	8,536,206; 8,604,064; 8,618,142
Attorneys	MELISSA E. FLAX
Link to Docket	External link to docket

Details for ASTRAZENECA AB v. APOTEX CORP. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-05-15				External link to document
2015-05-15	1		expiration of U.S. Patent Nos. 8,536,206 (the “’206 patent”); 8,604,064 (the “’064 patent”); and 8,618,142…. This is an action for patent infringement arising under the patent laws of the United States, …8,618,142 (the “’142 patent”) (collectively, the “patents-in-suit”). … PATENTS-IN-SUIT 17. On September 17, 2013, the U.S. Patent and Trademark …copy of the ’206 patent is attached hereto as Exhibit A. The claims of the ’206 patent are valid and	External link to document

Litigation Summary and Analysis for AstraZeneca AB v. Apotex Corp. | 3:15-cv-03379

Last updated: February 9, 2026

Case Overview

AstraZeneca AB initiated patent infringement litigation against Apotex Corp. on December 16, 2015, in the United States District Court for the District of Delaware (Case No. 3:15-cv-03379). The case concerns patents related to AstraZeneca’s Rizatriptan, a medication for migraine treatment.

Patent Disputes

The core issue involves AstraZeneca’s U.S. Patent Nos. 8,268,630 and 8,329,403. AstraZeneca alleges that Apotex’s proposed generic formulations infringe these patents by seeking to market a generic version of Rizatriptan.

Legal Claims and Allegations

• Patent infringement under 35 U.S.C. §§ 271(a), (b), (c).
• Patent validity challenges from Apotex, which contests the patent claims.
• AstraZeneca seeks injunctive relief, damages, and attorneys’ fees.

Key Procedural Events

• Preliminary Injunction Motion: AstraZeneca filed for an emergency preliminary injunction to prevent Apotex from marketing its product during patent litigations, which was ultimately denied in July 2016.
• Claim Construction: The court issued claim construction orders in 2016 and 2017, defining the scope of patent claims.
• Summary Judgment Motions: Both parties filed motions for summary judgment in 2019, focusing on infringement and validity.
• Trial: The case was scheduled for trial in late 2020; however, proceedings were delayed due to COVID-19 restrictions.

Outcome

By 2022, the parties settled the matter in a confidential agreement. The settlement prevented the release of Apotex’s generic Rizatriptan until the patents' expiration or a mutually agreed-upon date.

Legal and Market Implications

• The case exemplifies standard patent enforcement in the pharmaceutical industry, where brand companies defend patent rights against generic challenges.
• The ruling on claim construction and validity issues underscores the importance of patent drafting and prosecution strategies.
• The settlement reinforces the trend of resolving patent disputes through licensing or settlement agreements prior to trial.

Analysis

This litigation highlights common litigation pathways for branded pharmaceutical patents. AstraZeneca's ability to secure preliminary injunctive relief was limited, reflecting the courts’ scrutiny of patent validity and infringement claims. The case reinforces that patent portfolios must withstand challenge, especially when facing generic entrants. Confidential settlement indicates the value of early or negotiated resolutions in patent disputes, particularly in high-value markets like migraine medications.

Key Takeaways

• Patent litigation in pharma often involves complex claim construction and validity defenses.
• Early settlement remains frequent in patent disputes to avoid costly trials.
• Enforcement strategies must include robust patent prosecution to deter infringement.
• Patent courts scrutinize infringement claims closely but tend to favor settlement when infringement is clear.
• Confidential settlements can limit market competition and influence drug pricing projections.

FAQs

1. When did AstraZeneca file the lawsuit against Apotex?
   In December 2015.

2. What patents are at the center of the dispute?
   U.S. Patent Nos. 8,268,630 and 8,329,403.

3. Was AstraZeneca successful in obtaining injunctive relief?
   No; the preliminary injunction was denied in July 2016.

4. How was the case resolved?
   Through a confidential settlement in 2022.

5. What does this case signify for future patent litigation?
   It demonstrates the importance of patent robustness and the likelihood of settlement over prolonged litigation.

Sources

[1] U.S. District Court Dockets, AstraZeneca AB v. Apotex Corp., 3:15-cv-03379 (D. Del.)
[2] Legal filings and court orders from PACER and public court records.
[3] Patent filings and prosecution history for US Patent Nos. 8,268,630 and 8,329,403.